Gene · 910
Papers2,023
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,023
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identifying dendritic cell heterogeneity and potential risk genes in atopic dermatitis: integrative scRNA-seq, bulk RNA-seq analyses and experimental validation. | Front Med (Lausanne) | 2026 | 42718499 | PubTator, text mining | PubMed |
| Integrated experimental and computational evaluation of atractylenolide III from Tubipora musica for anticancer lead identification. | Sci Rep | 2026 | 42716976 | PubTator, text mining | PubMed |
| In vitro differentiation and phenotypic profiling of Langerhans cell subsets derived from human peripheral blood monocytes. | Immunol Res | 2026 | 42704586 | PubTator, text mining | PubMed |
| Newly customized cationic ẞ-cyclodextrins as potential nanovectors for gene delivery. | Int J Pharm | 2026 | 41916514 | PubTator, text mining | PubMed |
| Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering. | Cells | 2026 | 41892285 | PubTator, text mining | PubMed |
| Oligomeric lactic acid nanoplastics induce intrauterine growth restriction in mice by disrupting GATA2-mediated placental vascular development. | PLoS Biol | 2026 | 41886399 | PubTator, text mining | PubMed |
| Mechanistic insights into the therapeutic properties of delta opioid receptor. | Sci Adv | 2026 | 41880505 | PubTator, text mining | PubMed |
| Whole transcriptome sequencing identifies key characteristics and potential therapeutic efficacy biomarkers CD1B, CD247, and CCNB1 in cured tuberculosis patients. | Int J Infect Dis | 2026 | 41871736 | PubTator, text mining | PubMed |
| Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment. | Int J Nanomedicine | 2026 | 41783547 | PubTator, text mining | PubMed |
| Correction: Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses. | Front Immunol | 2026 | 41766885 | PubTator, text mining | PubMed |
| T Cell Receptor Co-Stimulation Through Magnetogenetic Tools: A Platform for Wireless Rewiring of Cellular Signaling. | ACS Omega | 2026 | 41726657 | PubTator, text mining | PubMed |
| Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram. | Ann Hematol | 2026 | 41692873 | PubTator, text mining | PubMed |
| First Report of Hb Oslo [HBB:c.127T>A; β42(CD1)Phe→Ile] from India and its Novel Compound Heterozygous Combination with IVS1-5 G>C [HBB:c.92+ 5G> C] Leading To β-Thalassemia Major. | Cell Biochem Biophys | 2026 | 41557141 | PubTator, text mining | PubMed |
| Nasal Gene Expression in ART-Naive Adults with HIV and Pulmonary Tuberculosis in Uganda. | medRxiv | 2026 | 41542684 | PubTator, text mining | PubMed |
| BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis. | Cell Rep Med | 2026 | 41529694 | PubTator, text mining | PubMed |
| Emerging Roles of CD1 and Lipids in Human Health and Disease. | Annu Rev Immunol | 2026 | 41364921 | PubTator, text mining | PubMed |
| Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses. | Front Immunol | 2025 | 41306962 | PubTator, text mining | PubMed |
| IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy. | Oncoimmunology | 2025 | 40996786 | PubTator, text mining | PubMed |
| Potential applications of lactic acid bacteria from Egyptian dairy products as novel antioxidant and anticancer agents. | Biotechnol Lett | 2025 | 40965691 | PubTator, text mining | PubMed |
| Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy. | Nat Commun | 2025 | 40855052 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/910/papers